Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Perspective Therapeutics (CATX)
NYSE MKT:CATX
RESEARCH TOOLSreports
Holding CATX?
Track your performance easily
CATX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.28 - $19.05
Previous Close$3
Volume7.93M
Average Volume (3M)1.15M
Market Cap
$235.88M
Enterprise Value-$60.82M
Total Cash (Recent Filing)$267.85M
Total Debt (Recent Filing)$4.27M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Mar 27, 2025EPS Estimate
-$0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding67,587,540
10 Day Avg. Volume1,196,106
30 Day Avg. Volume1,148,655
Standard Deviation0.46
R-Squared0.03
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)1.27
Price to Sales (P/S)375.61
Price to Cash Flow (P/CF)34.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-13.64
Enterprise Value/Gross Profit-42.41
Enterprise Value/Ebitda1.32
Forecast
1Y Price Target
$21.00Price Target Upside501.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Perspective Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessA striking overall response rate of 61.5% was observed in the trial, with 76.9% ORR including two unconfirmed PRs.
Market OpportunityVMT01 is targeting a significant market opportunity in metastatic melanoma, with preclinical data showing synergistic activity when combined with anti-PD1, potentially enhancing the abscopal effect.
Stock ValuationThe current valuation of the stock is considered a near-term overreaction, potentially representing a buying opportunity for those with long-term conviction.
Bears Say
Efficacy ConcernsInterim data from the VMT-alpha-NET trial left investors disappointed, falling short of expectations.
Market RiskThe probability of success for VMT01 in melanoma is adjusted from 35% to 20%, leading to a reduction in the price target.
Safety And Dosing IssuesThe Safety Monitoring Committee (SMC) recommended studying a lower dose level of 1.5 mCi/dose due to concerns over high estimated kidney dose.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CATX FAQ
What was Perspective Therapeutics’s price range in the past 12 months?
Perspective Therapeutics lowest stock price was $2.28 and its highest was $19.05 in the past 12 months.
What is Perspective Therapeutics’s market cap?
Currently, no data Available
When is Perspective Therapeutics’s upcoming earnings report date?
Perspective Therapeutics’s upcoming earnings report date is Mar 27, 2025 which is in 124 days.
How were Perspective Therapeutics’s earnings last quarter?
Perspective Therapeutics released its earnings results on Nov 12, 2024. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.213 by $0.003.
Is Perspective Therapeutics overvalued?
According to Wall Street analysts Perspective Therapeutics’s price is currently Undervalued.
Does Perspective Therapeutics pay dividends?
Perspective Therapeutics does not currently pay dividends.
What is Perspective Therapeutics’s EPS estimate?
Perspective Therapeutics’s EPS estimate is -$0.26.
How many shares outstanding does Perspective Therapeutics have?
Perspective Therapeutics has 67,587,540 shares outstanding.
What happened to Perspective Therapeutics’s price movement after its last earnings report?
Perspective Therapeutics reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.213. Following the earnings report the stock price went down -6.935%.
Which hedge fund is a major shareholder of Perspective Therapeutics?
Among the largest hedge funds holding Perspective Therapeutics’s share is Deerfield Management Company, LP. It holds Perspective Therapeutics’s shares valued at 38M.
---
Perspective Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.00 (501.72% Upside)
$21.00 (501.72% Upside)
Blogger Sentiment
Bullish
CATX Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 9.9%
Last 30 Days ▲ 9.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
16.23%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
253.93%
Trailing 12-Months
Company Description
Perspective Therapeutics
IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.
---
CATX Stock 12 Month Forecast
Average Price Target
$21.00
▲(501.72% Upside)
Technical Analysis
Best Analysts Covering CATX
1 Year
1 Year Success Rate
5/12 ratings generated profit
1 Year Average Return
+35.68%
reiterated a buy rating 10 days ago
Copying Jeff Jones's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of +35.68% per trade.
---